Peptides and the PCAC Hearing: FAQ

New to all of this? Start with Peptides and Safe Access, Explained for Everyone.

The hearing

1. What was the PCAC hearing, and what did it decide?

The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA. On July 23 and 24, 2026, it met in public to consider whether licensed pharmacies can prepare certain peptide therapies for patients who have a valid prescription. It voted to recommend six of the seven peptides it reviewed (BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon) for the 503A bulks list. It did not recommend DSIP. See the results and watch the recordings.

2. What is at stake for patients?

Safe, regulated access. If the regulated path narrows, patients who rely on these therapies do not stop seeking them. They get pushed toward an unregulated gray market, with no quality control, no verified dosing, and no medical supervision. The goal is to keep access in safe, accountable channels.

3. What is compounding?

Compounding is when a licensed pharmacist prepares a medication for a specific patient, for example at a different dose or without an ingredient the patient reacts to. Accredited 503A pharmacies (regulated by state boards of pharmacy) and 503B outsourcing facilities (registered with and inspected by the FDA) are held to federal and state standards for quality.

4. What happened in 2023?

A compounding-eligibility decision under regulatory review restricted a set of peptides from being compounded. The therapies did not disappear; many patients were pushed toward an unregulated gray market instead. This is not a story about a ban. It is about access moving out of regulated, accountable channels, and the July 2026 review was a chance to start correcting that.

5. Does the vote mean these peptides are now legal to compound?

Not yet. A PCAC vote is a recommendation to the FDA, not a final rule, and it does not change current access rules on its own. The FDA now decides what to do with that advice through formal rule-making.

Peptides and the gray market

6. What is a peptide?

A peptide is a short chain of amino acids, the building blocks of proteins. Your body makes thousands of them. Insulin has been a peptide medicine for over a century, and peptides occur naturally in everyday foods. The word itself is not what makes a therapy safe or risky; the source and the supervision are.

7. What is the “gray market,” and why is it dangerous?

It is the unregulated channel where these therapies are sold without oversight: online vendors and products labeled “for research use only.” There is no inspection, no verified quality or dosing, and no clinical supervision. Most documented safety problems are associated with this kind of self-sourcing, which is exactly what a regulated, supervised pathway is built to prevent.

8. What does AAPM (American Academy of Peptide Medicine) want?

To protect safe, regulated access to peptide therapies. AAPM (American Academy of Peptide Medicine) is pro-access and pro-safety at the same time. The fix for the gray market is rigor and supervision, not prohibition, and not deregulation. AAPM (American Academy of Peptide Medicine) works with regulators and industry to set the quality standards that make a safe, regulated pathway possible.

What happens next

9. Can I still comment on the hearing?

No. The public comment period closed on July 22, 2026, and about 1,900 comments went into the record. You can browse them here.

10. What happens after the vote?

The FDA weighs the committee’s recommendation and decides whether to add these peptides to the 503A bulks list through formal rule-making. That process can include another chance for public input. We will share it here when it opens.

11. How can I help now?

Tell your elected officials that patients need safe, regulated access to peptide therapy. Write your representative in a few minutes, and follow state and federal bills on the Legislative Tracker.

12. Do I have to be an expert?

No. You just have to be someone this affects. Patients, caregivers, pharmacists, and clinicians all have a standing reason to speak up. Speak from your own experience.